The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Site Search
Showing 1 - 4 of 4 results
Press Release
|
March 29, 2022
|
4 min read
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
Press Release
|
Jan. 4, 2022
|
4 min read
Back in 2015, my genetic sequencing revealed one nonsense mutation. But recently, I learned I have another nonsense mutation that may not have been identified when my genes were first sequenced. As more mutation-dependent therapies are developed, it’s crucial that people with CF have accurate information so they can make informed decisions.
Steph Hansen
|
6 min read
For those of us who can’t take modulators, it can sometimes feel like you’ve been left behind. But I have found hope and motivation by participating in clinical trials.
Schyler Kline
|
5 min read